Hereditary Optic Atrophies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hereditary optic atrophies markets are expected to exhibit a CAGR of 4.38% during 2024-2034.
The hereditary optic atrophies market has been comprehensively analyzed in IMARC's new report titled "Hereditary Optic Atrophies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hereditary optic atrophies (HOAs) encompass a group of rare genetic disorders characterized by the progressive degeneration of the optic nerve, which links the eye to the brain. This condition is primarily inherited through a family's genetic lineage and can manifest in various ways, making early diagnosis crucial. The symptoms of HOAs typically emerge gradually and often include a gradual loss of central and peripheral vision, decreased visual acuity, color vision impairment, and sometimes the development of a pale or waxy appearance to the optic nerve head during an eye examination. Individuals suffering from this illness may also experience indications, such as difficulty with contrast sensitivity and challenges with tasks requiring fine visual discrimination. The diagnosis of HOAs involves a thorough medical history review, a comprehensive eye examination, and specialized tests like visual field testing, optical coherence tomography (OCT), and genetic testing to identify the specific mutation responsible for the condition.
The escalating prevalence of mutations in genes like OPA1 and WFS1, which lead to the degeneration of optic nerves and affect vision, is primarily driving the hereditary optic atrophies market. In addition to this, the inflating utilization of potent medications, including antioxidants and neuroprotective agents, aimed at slowing down the rate of vision loss and enhancing mitochondrial function, is also creating a positive outlook for the market. Moreover, the widespread adoption of rehabilitative measures like low vision aids and orientation mobility training, designed to help individuals suffering from HOAs adapt to vision loss and improve their quality of life, is further bolstering the market growth. Apart from this, the rising usage of stem cell therapy and gene therapy, since they focus on replacing or repairing the defective genetic material responsible for optic nerve degeneration, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of bioinformatics, which can offer more precise genetic testing, thereby allowing for the identification of gene mutations and enabling targeted therapies, is also augmenting the market growth. Furthermore, the increasing application of optogenetics, a cutting-edge field that involves the use of light-sensitive proteins to restore vision by stimulating retinal cells, is expected to drive the hereditary optic atrophies market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hereditary optic atrophies market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hereditary optic atrophies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hereditary optic atrophies market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hereditary optic atrophies market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hereditary optic atrophies market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hereditary optic atrophies marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hereditary optic atrophies market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hereditary optic atrophies market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hereditary optic atrophies market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hereditary optic atrophies across the seven major markets?
What is the number of prevalent cases (2018-2034) of hereditary optic atrophies by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hereditary optic atrophies by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hereditary optic atrophies across the seven major markets?
What is the size of the hereditary optic atrophies patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hereditary optic atrophies?
What will be the growth rate of patients across the seven major markets?
Hereditary Optic Atrophies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hereditary optic atrophies drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hereditary optic atrophies market?
What are the key regulatory events related to the hereditary optic atrophies market?
What is the structure of clinical trial landscape by status related to the hereditary optic atrophies market?
What is the structure of clinical trial landscape by phase related to the hereditary optic atrophies market?
What is the structure of clinical trial landscape by route of administration related to the hereditary optic atrophies market?
The hereditary optic atrophies market has been comprehensively analyzed in IMARC's new report titled "Hereditary Optic Atrophies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hereditary optic atrophies (HOAs) encompass a group of rare genetic disorders characterized by the progressive degeneration of the optic nerve, which links the eye to the brain. This condition is primarily inherited through a family's genetic lineage and can manifest in various ways, making early diagnosis crucial. The symptoms of HOAs typically emerge gradually and often include a gradual loss of central and peripheral vision, decreased visual acuity, color vision impairment, and sometimes the development of a pale or waxy appearance to the optic nerve head during an eye examination. Individuals suffering from this illness may also experience indications, such as difficulty with contrast sensitivity and challenges with tasks requiring fine visual discrimination. The diagnosis of HOAs involves a thorough medical history review, a comprehensive eye examination, and specialized tests like visual field testing, optical coherence tomography (OCT), and genetic testing to identify the specific mutation responsible for the condition.
The escalating prevalence of mutations in genes like OPA1 and WFS1, which lead to the degeneration of optic nerves and affect vision, is primarily driving the hereditary optic atrophies market. In addition to this, the inflating utilization of potent medications, including antioxidants and neuroprotective agents, aimed at slowing down the rate of vision loss and enhancing mitochondrial function, is also creating a positive outlook for the market. Moreover, the widespread adoption of rehabilitative measures like low vision aids and orientation mobility training, designed to help individuals suffering from HOAs adapt to vision loss and improve their quality of life, is further bolstering the market growth. Apart from this, the rising usage of stem cell therapy and gene therapy, since they focus on replacing or repairing the defective genetic material responsible for optic nerve degeneration, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of bioinformatics, which can offer more precise genetic testing, thereby allowing for the identification of gene mutations and enabling targeted therapies, is also augmenting the market growth. Furthermore, the increasing application of optogenetics, a cutting-edge field that involves the use of light-sensitive proteins to restore vision by stimulating retinal cells, is expected to drive the hereditary optic atrophies market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hereditary optic atrophies market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hereditary optic atrophies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hereditary optic atrophies market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hereditary optic atrophies market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hereditary optic atrophies market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hereditary optic atrophies marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hereditary optic atrophies market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hereditary optic atrophies market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hereditary optic atrophies market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hereditary optic atrophies across the seven major markets?
What is the number of prevalent cases (2018-2034) of hereditary optic atrophies by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hereditary optic atrophies by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hereditary optic atrophies across the seven major markets?
What is the size of the hereditary optic atrophies patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hereditary optic atrophies?
What will be the growth rate of patients across the seven major markets?
Hereditary Optic Atrophies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hereditary optic atrophies drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hereditary optic atrophies market?
What are the key regulatory events related to the hereditary optic atrophies market?
What is the structure of clinical trial landscape by status related to the hereditary optic atrophies market?
What is the structure of clinical trial landscape by phase related to the hereditary optic atrophies market?
What is the structure of clinical trial landscape by route of administration related to the hereditary optic atrophies market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEREDITARY OPTIC ATROPHIES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HEREDITARY OPTIC ATROPHIES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEREDITARY OPTIC ATROPHIES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HEREDITARY OPTIC ATROPHIES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEREDITARY OPTIC ATROPHIES - UNMET NEEDS
10 HEREDITARY OPTIC ATROPHIES - KEY ENDPOINTS OF TREATMENT
11 HEREDITARY OPTIC ATROPHIES - MARKETED PRODUCTS
11.1 List of Hereditary Optic Atrophies Marketed Drugs Across the Top 7 Markets
11.1.1 Raxone (Idebenone) - Santhera Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HEREDITARY OPTIC ATROPHIES - PIPELINE DRUGS
12.1 List of Hereditary Optic Atrophies Pipeline Drugs Across the Top 7 Markets
12.1.1 GS010 - GenSight Biologics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HEREDITARY OPTIC ATROPHIES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HEREDITARY OPTIC ATROPHIES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HEREDITARY OPTIC ATROPHIES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hereditary Optic Atrophies - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hereditary Optic Atrophies - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hereditary Optic Atrophies - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hereditary Optic Atrophies - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hereditary Optic Atrophies - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hereditary Optic Atrophies - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hereditary Optic Atrophies - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hereditary Optic Atrophies - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hereditary Optic Atrophies - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hereditary Optic Atrophies - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hereditary Optic Atrophies - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hereditary Optic Atrophies - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hereditary Optic Atrophies - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hereditary Optic Atrophies - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hereditary Optic Atrophies - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hereditary Optic Atrophies - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
16 HEREDITARY OPTIC ATROPHIES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HEREDITARY OPTIC ATROPHIES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HEREDITARY OPTIC ATROPHIES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEREDITARY OPTIC ATROPHIES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HEREDITARY OPTIC ATROPHIES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEREDITARY OPTIC ATROPHIES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HEREDITARY OPTIC ATROPHIES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEREDITARY OPTIC ATROPHIES - UNMET NEEDS
10 HEREDITARY OPTIC ATROPHIES - KEY ENDPOINTS OF TREATMENT
11 HEREDITARY OPTIC ATROPHIES - MARKETED PRODUCTS
11.1 List of Hereditary Optic Atrophies Marketed Drugs Across the Top 7 Markets
11.1.1 Raxone (Idebenone) - Santhera Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HEREDITARY OPTIC ATROPHIES - PIPELINE DRUGS
12.1 List of Hereditary Optic Atrophies Pipeline Drugs Across the Top 7 Markets
12.1.1 GS010 - GenSight Biologics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HEREDITARY OPTIC ATROPHIES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HEREDITARY OPTIC ATROPHIES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HEREDITARY OPTIC ATROPHIES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hereditary Optic Atrophies - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hereditary Optic Atrophies - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hereditary Optic Atrophies - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hereditary Optic Atrophies - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hereditary Optic Atrophies - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hereditary Optic Atrophies - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hereditary Optic Atrophies - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hereditary Optic Atrophies - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hereditary Optic Atrophies - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hereditary Optic Atrophies - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hereditary Optic Atrophies - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hereditary Optic Atrophies - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hereditary Optic Atrophies - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hereditary Optic Atrophies - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hereditary Optic Atrophies - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hereditary Optic Atrophies - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hereditary Optic Atrophies - Access and Reimbursement Overview
16 HEREDITARY OPTIC ATROPHIES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HEREDITARY OPTIC ATROPHIES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HEREDITARY OPTIC ATROPHIES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
